Determining the effects of SGLT2 inhibitor on breast cancer cell migration and clonogenicity - a pilot study.

IF 1.5 4区生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

General physiology and biophysics Pub Date : 2026-03-01 DOI:10.4149/gpb_2025044

Vincent Lučanský, Ivana Baranová, Iryna Samec, Martin Jozef Péč, Renata Péčová, Marek Samec

{"title":"Determining the effects of SGLT2 inhibitor on breast cancer cell migration and clonogenicity - a pilot study.","authors":"Vincent Lučanský, Ivana Baranová, Iryna Samec, Martin Jozef Péč, Renata Péčová, Marek Samec","doi":"10.4149/gpb_2025044","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer remains one of the most diagnosed and lethal cancers, with increased incidence in developing countries. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is an effective and well-tolerated antidiabetic drug for managing and treating type 2 diabetes mellitus. Moreover, it can reduce the risk of death from cardiovascular causes and hospitalizations for heart failure. Recent data indicate that empagliflozin has antioxidant and anti-inflammatory effects mediated by modulating various signaling pathways. Molecular and cellular analysis revealed that SGLT2 is expressed in different types of cancer, including breast, cervical, and lung. We analyzed the potential anticancer activities of empagliflozin in the 4T1 breast cancer cell line. To assess the effect of the SGLT2 inhibitor on the migration and clonogenicity of cancer cells, we used the wound healing assay and the colony formation assay. The acquired data showed some trends; however, no significant results were obtained.</p>","PeriodicalId":12514,"journal":{"name":"General physiology and biophysics","volume":"45 2","pages":"219-223"},"PeriodicalIF":1.5000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"General physiology and biophysics","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.4149/gpb_2025044","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Breast cancer remains one of the most diagnosed and lethal cancers, with increased incidence in developing countries. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is an effective and well-tolerated antidiabetic drug for managing and treating type 2 diabetes mellitus. Moreover, it can reduce the risk of death from cardiovascular causes and hospitalizations for heart failure. Recent data indicate that empagliflozin has antioxidant and anti-inflammatory effects mediated by modulating various signaling pathways. Molecular and cellular analysis revealed that SGLT2 is expressed in different types of cancer, including breast, cervical, and lung. We analyzed the potential anticancer activities of empagliflozin in the 4T1 breast cancer cell line. To assess the effect of the SGLT2 inhibitor on the migration and clonogenicity of cancer cells, we used the wound healing assay and the colony formation assay. The acquired data showed some trends; however, no significant results were obtained.

查看原文本刊更多论文

确定SGLT2抑制剂对乳腺癌细胞迁移和克隆性的影响-一项初步研究。

乳腺癌仍然是诊断最多和最致命的癌症之一，在发展中国家发病率增加。恩格列净是一种钠-葡萄糖共转运蛋白2 （SGLT2）抑制剂，是一种有效且耐受性良好的抗糖尿病药物，用于控制和治疗2型糖尿病。此外，它还可以降低因心血管原因死亡和因心力衰竭住院的风险。最近的研究表明，恩格列净通过调节多种信号通路具有抗氧化和抗炎作用。分子和细胞分析显示SGLT2在不同类型的癌症中表达，包括乳腺癌、宫颈癌和肺癌。我们分析了恩格列净在4T1乳腺癌细胞系中的潜在抗癌活性。为了评估SGLT2抑制剂对癌细胞迁移和克隆性的影响，我们使用了伤口愈合实验和集落形成实验。获得的数据显示出一些趋势；然而，没有得到显著的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

General physiology and biophysics 生物-生化与分子生物学

CiteScore

2.70

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： General Physiology and Biophysics is devoted to the publication of original research papers concerned with general physiology, biophysics and biochemistry at the cellular and molecular level and is published quarterly by the Institute of Molecular Physiology and Genetics, Slovak Academy of Sciences.